You are here: Home » News-CM » Companies » News
Business Standard

Marksans Pharma gets ANDA approval for Paricalcitol Capsules

Capital Market 

From USFDA

announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Marksans Pharma gets ANDA approval for Paricalcitol Capsules

From USFDA

From USFDA

announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Marksans Pharma gets ANDA approval for Paricalcitol Capsules

From USFDA

announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22